Published in Cancer Causes Control on May 13, 2009
Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol (2010) 2.26
Updated evidence in support of diet and exercise interventions in cancer survivors. Acta Oncol (2010) 1.87
Recommendations for high-priority research on cancer-related fatigue in children and adults. J Natl Cancer Inst (2013) 1.11
Effects of a physical activity behavior change intervention on inflammation and related health outcomes in breast cancer survivors: pilot randomized trial. Integr Cancer Ther (2012) 1.03
Changes in insulin resistance indicators, IGFs, and adipokines in a year-long trial of aerobic exercise in postmenopausal women. Endocr Relat Cancer (2011) 1.01
Effects of a 12-week home-based exercise program on the level of physical activity, insulin, and cytokines in colorectal cancer survivors: a pilot study. Support Care Cancer (2013) 0.94
Water versus land-based multimodal exercise program effects on body composition in breast cancer survivors: a controlled clinical trial. Support Care Cancer (2012) 0.88
Race, age, and obesity disparities in adult physical activity levels in breast cancer patients and controls. Front Public Health (2014) 0.86
A Community-Based Exercise and Support Group Program in African-American Breast Cancer Survivors (ABCs). J Phys Ther Health Promot (2013) 0.82
Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol (2013) 0.81
The effect of aerobic exercise on serum C - reactive protein and leptin levels in untrained middle-aged women. Iran J Public Health (2012) 0.77
Circulating High-Molecular-Weight (HMW) Adiponectin Level Is Related with Breast Cancer Risk Better than Total Adiponectin: A Case-Control Study. PLoS One (2015) 0.77
Bootcamp during neoadjuvant chemotherapy for breast cancer: a randomized pilot trial. Breast Cancer (Auckl) (2012) 0.76
Adiponectin, Leptin and Objectively Measured Physical Activity in Adults: A Narrative Review. Malays J Med Sci (2016) 0.75
Effects of Exercise Training on Physical Fitness and Biomarker Levels in Breast Cancer Survivors. J Lifestyle Med (2017) 0.75
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Open mesh versus laparoscopic mesh repair of inguinal hernia. N Engl J Med (2004) 8.24
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A (2009) 6.67
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Watchful waiting vs repair of inguinal hernia in minimally symptomatic men: a randomized clinical trial. JAMA (2006) 6.34
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer (2007) 5.57
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med (2004) 4.87
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
CNS metastases in breast cancer. J Clin Oncol (2004) 4.42
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med (2009) 4.16
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol (2004) 4.03
Informing clinical trial participants about study results. JAMA (2002) 3.76
FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism (2012) 3.61
Dietary patterns and risk of mortality from cardiovascular disease, cancer, and all causes in a prospective cohort of women. Circulation (2008) 3.56
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol (2011) 3.53
Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation (2009) 3.47
Local therapy and survival in breast cancer. N Engl J Med (2007) 3.33
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst (2005) 3.22
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol (2008) 3.04
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res (2009) 2.90
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer (2008) 2.82
Brain metastases: the HER2 paradigm. Clin Cancer Res (2007) 2.81
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst (2009) 2.77
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med (2013) 2.76
The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer (2010) 2.63
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res (2012) 2.63
Leptin in immunology. J Immunol (2005) 2.62
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care (2004) 2.55
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol (2011) 2.51
The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) (2012) 2.50
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest (2003) 2.42
Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr (2007) 2.40
Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol (2013) 2.35
Do patients participating in clinical trials want to know study results? J Natl Cancer Inst (2003) 2.33
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 2.32
American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol (2011) 2.30
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst (2010) 2.28
Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab (2003) 2.25
Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol (2006) 2.24
Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr (2009) 2.22
Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab (2013) 2.16
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw (2006) 2.15
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab (2003) 2.09
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol (2005) 2.09
Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev (2010) 2.09
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol (2012) 2.07
Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab (2007) 2.07
Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: a prospective cohort study. Diabetes Care (2007) 2.06
Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2012) 2.04
Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care (2007) 2.04
The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology (2002) 2.03
Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med (2008) 2.01
Does resident post graduate year influence the outcomes of inguinal hernia repair? Ann Surg (2005) 2.01
Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med (2010) 2.00
Sleep duration and snoring in relation to biomarkers of cardiovascular disease risk among women with type 2 diabetes. Diabetes Care (2007) 1.99
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev (2007) 1.95
Offering participants results of a clinical trial: sharing results of a negative study. Lancet (2005) 1.90
Drug Insight: the role of leptin in human physiology and pathophysiology--emerging clinical applications. Nat Clin Pract Endocrinol Metab (2006) 1.88
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw (2006) 1.88
Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab (2004) 1.86
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol (2007) 1.85
Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab (2003) 1.84
Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism (2010) 1.81
Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab (2005) 1.81
The role of adiponectin in cancer: a review of current evidence. Endocr Rev (2012) 1.78
Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol (2007) 1.77
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol (2011) 1.72